{"id":48753,"date":"2025-11-21T21:39:21","date_gmt":"2025-11-21T13:39:21","guid":{"rendered":"https:\/\/flcube.com\/?p=48753"},"modified":"2025-11-21T21:39:22","modified_gmt":"2025-11-21T13:39:22","slug":"reprogenix-closes-rmb-500m-series-a-to-advance-diabetes-cell-therapy-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48753","title":{"rendered":"Reprogenix Closes RMB 500M Series A+ to Advance Diabetes Cell Therapy Pipeline"},"content":{"rendered":"\n<p><strong>Reprogenix Bioscience Inc.<\/strong> announced the completion of an oversubscribed <strong>RMB 500\u202fmillion Series\u202fA+<\/strong> financing round led by <strong>CRS Fund<\/strong> and joined by <strong>Yuanbio Venture Capital, ZSCO, SinoWisdom, Oriental Renaissance Capital, Lotus Lake Capital, Yuhang State\u2011owned Capital Investment, Beijing Gage, and Beicheng Fund<\/strong>. Proceeds will accelerate clinical advancement of its diabetes cell therapies, develop an <strong>AI\u2011driven islet differentiation platform<\/strong>, and expand digital manufacturing capacity.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financing-details\">Financing Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Reprogenix Bioscience Inc.<\/td><\/tr><tr><td><strong>Amount<\/strong><\/td><td>RMB 500\u202fmillion (Series\u202fA+)<\/td><\/tr><tr><td><strong>Lead Investor<\/strong><\/td><td>CRS Fund<\/td><\/tr><tr><td><strong>Co\u2011Investors<\/strong><\/td><td>Yuanbio Venture Capital, ZSCO, SinoWisdom, Oriental Renaissance Capital, Lotus Lake Capital, Yuhang State\u2011owned Capital Investment, Beijing Gage, Beicheng Fund<\/td><\/tr><tr><td><strong>Use of Proceeds<\/strong><\/td><td>Clinical advancement, AI islet platform, automated production, global expansion<\/td><\/tr><tr><td><strong>Valuation<\/strong><\/td><td>Not disclosed; post\u2011money estimated at RMB 2.0\u20112.5\u202fbillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-company-profile\">Company Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Founded:<\/strong> 2014<\/li>\n\n\n\n<li><strong>Focus:<\/strong> Cell therapy for <strong>Type\u202f1 and Type\u202f2 diabetes<\/strong><\/li>\n\n\n\n<li><strong>Pipeline:<\/strong> Two core assets in clinical\/late preclinical stage<\/li>\n\n\n\n<li><strong>Technology:<\/strong> <strong>AI virtual cell<\/strong> platform for islet differentiation; digital, intelligent, automated GMP manufacturing<\/li>\n\n\n\n<li><strong>Strategic Edge:<\/strong> <strong>First domestic company<\/strong> with Type\u202f1 diabetes cell therapy in Phase\u202fI<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-overview\">Pipeline Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Indication<\/th><th>Stage<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>RGB\u20115088<\/strong><\/td><td>Type\u202f1 diabetes<\/td><td>Phase\u202fI<\/td><td>Approved for clinical trial; <strong>leading domestically<\/strong><\/td><\/tr><tr><td><strong>RGB\u2011T2D<\/strong>*<\/td><td>Type\u202f2 diabetes<\/td><td>IND\u2011enabling<\/td><td>Clinical trial application accepted by NMPA; entry imminent<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>*Internal code; branded name pending<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-platform\">Technology Platform<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AI Virtual Cells:<\/strong> Accelerates islet differentiation protocol optimization, reducing development time by <strong>30\u201140%<\/strong> vs. traditional methods<\/li>\n\n\n\n<li><strong>Automated Manufacturing:<\/strong> Closed\u2011system bioreactors and AI\u2011driven quality control enable <strong>scale\u2011up to 10,000+ doses\/year<\/strong> per facility<\/li>\n\n\n\n<li><strong>Cost Position:<\/strong> Targeting <strong>60\u201170% cost reduction<\/strong> vs. manual production, critical for diabetes cell therapy commercial viability<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>China Diabetes Patients<\/strong><\/td><td>141\u202fmillion (Type\u202f2: 90%; Type\u202f1: ~1\u202fmillion)<\/td><\/tr><tr><td><strong>Cell Therapy Penetration Target<\/strong><\/td><td>Type\u202f1: 5% (50,000 patients); Type\u202f2: 0.1% (140,000 patients)<\/td><\/tr><tr><td><strong>Pricing<\/strong><\/td><td>Type\u202f1: \u00a5150,000\u2011200,000\/dose; Type\u202f2: \u00a580,000\u2011120,000\/dose<\/td><\/tr><tr><td><strong>Peak Market Potential<\/strong><\/td><td><strong>\u00a550\u201170\u202fbillion<\/strong> (US$7\u201110\u202fbillion) by 2035<\/td><\/tr><tr><td><strong>Manufacturing Capacity<\/strong><\/td><td>First GMP facility (Hangzhou) operational 2026; second facility (Sichuan) planned 2027<\/td><\/tr><tr><td><strong>Global Strategy<\/strong><\/td><td>Partnership discussions underway for US\/EU Phase\u202fI trials; leveraging AI platform for IND\u2011ready packages<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Competitive Moat:<\/strong> Only domestic player in Phase\u202fI for Type\u202f1; multinational rivals (e.g., <strong>Vertex<\/strong> via ViaCyte, <strong>Sana Biotechnology<\/strong>) remain pre\u2011clinical or early clinical in China.<\/li>\n\n\n\n<li><strong>Reimbursement Path:<\/strong> Type\u202f1 cell therapy likely to receive <strong>breakthrough designation<\/strong> and priority NRDL review; Type\u202f2 may require real\u2011world evidence for broader coverage.<\/li>\n\n\n\n<li><strong>Funding Runway:<\/strong> Series\u202fA+ extends runway to <strong>Q4\u202f2027<\/strong>, enabling two Phase\u202fI readouts and Type\u202f2 IND filing.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Reprogenix\u2019s clinical development, manufacturing scale\u2011up, and market penetration. Actual results may differ materially due to risks including clinical trial outcomes, regulatory review timelines, and competitive dynamics in cell therapy.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Reprogenix Bioscience Inc. announced the completion of an oversubscribed RMB 500\u202fmillion Series\u202fA+ financing round led&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48754,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[1905],"class_list":["post-48753","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-reprogenix"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Reprogenix Closes RMB 500M Series A+ to Advance Diabetes Cell Therapy Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Reprogenix Bioscience Inc. announced the completion of an oversubscribed RMB 500\u202fmillion Series\u202fA+ financing round led by CRS Fund and joined by Yuanbio Venture Capital, ZSCO, SinoWisdom, Oriental Renaissance Capital, Lotus Lake Capital, Yuhang State\u2011owned Capital Investment, Beijing Gage, and Beicheng Fund. Proceeds will accelerate clinical advancement of its diabetes cell therapies, develop an AI\u2011driven islet differentiation platform, and expand digital manufacturing capacity.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48753\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Reprogenix Closes RMB 500M Series A+ to Advance Diabetes Cell Therapy Pipeline\" \/>\n<meta property=\"og:description\" content=\"Reprogenix Bioscience Inc. announced the completion of an oversubscribed RMB 500\u202fmillion Series\u202fA+ financing round led by CRS Fund and joined by Yuanbio Venture Capital, ZSCO, SinoWisdom, Oriental Renaissance Capital, Lotus Lake Capital, Yuhang State\u2011owned Capital Investment, Beijing Gage, and Beicheng Fund. Proceeds will accelerate clinical advancement of its diabetes cell therapies, develop an AI\u2011driven islet differentiation platform, and expand digital manufacturing capacity.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48753\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-21T13:39:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-21T13:39:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2102.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48753#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48753\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Reprogenix Closes RMB 500M Series A+ to Advance Diabetes Cell Therapy Pipeline\",\"datePublished\":\"2025-11-21T13:39:21+00:00\",\"dateModified\":\"2025-11-21T13:39:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48753\"},\"wordCount\":444,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48753#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2102.webp\",\"keywords\":[\"Reprogenix\"],\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48753#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48753\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48753\",\"name\":\"Reprogenix Closes RMB 500M Series A+ to Advance Diabetes Cell Therapy Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48753#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48753#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2102.webp\",\"datePublished\":\"2025-11-21T13:39:21+00:00\",\"dateModified\":\"2025-11-21T13:39:22+00:00\",\"description\":\"Reprogenix Bioscience Inc. announced the completion of an oversubscribed RMB 500\u202fmillion Series\u202fA+ financing round led by CRS Fund and joined by Yuanbio Venture Capital, ZSCO, SinoWisdom, Oriental Renaissance Capital, Lotus Lake Capital, Yuhang State\u2011owned Capital Investment, Beijing Gage, and Beicheng Fund. Proceeds will accelerate clinical advancement of its diabetes cell therapies, develop an AI\u2011driven islet differentiation platform, and expand digital manufacturing capacity.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48753#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48753\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48753#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2102.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2102.webp\",\"width\":1080,\"height\":608,\"caption\":\"Reprogenix Closes RMB 500M Series A+ to Advance Diabetes Cell Therapy Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48753#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Reprogenix Closes RMB 500M Series A+ to Advance Diabetes Cell Therapy Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Reprogenix Closes RMB 500M Series A+ to Advance Diabetes Cell Therapy Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Reprogenix Bioscience Inc. announced the completion of an oversubscribed RMB 500\u202fmillion Series\u202fA+ financing round led by CRS Fund and joined by Yuanbio Venture Capital, ZSCO, SinoWisdom, Oriental Renaissance Capital, Lotus Lake Capital, Yuhang State\u2011owned Capital Investment, Beijing Gage, and Beicheng Fund. Proceeds will accelerate clinical advancement of its diabetes cell therapies, develop an AI\u2011driven islet differentiation platform, and expand digital manufacturing capacity.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48753","og_locale":"en_US","og_type":"article","og_title":"Reprogenix Closes RMB 500M Series A+ to Advance Diabetes Cell Therapy Pipeline","og_description":"Reprogenix Bioscience Inc. announced the completion of an oversubscribed RMB 500\u202fmillion Series\u202fA+ financing round led by CRS Fund and joined by Yuanbio Venture Capital, ZSCO, SinoWisdom, Oriental Renaissance Capital, Lotus Lake Capital, Yuhang State\u2011owned Capital Investment, Beijing Gage, and Beicheng Fund. Proceeds will accelerate clinical advancement of its diabetes cell therapies, develop an AI\u2011driven islet differentiation platform, and expand digital manufacturing capacity.","og_url":"https:\/\/flcube.com\/?p=48753","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-21T13:39:21+00:00","article_modified_time":"2025-11-21T13:39:22+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2102.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48753#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48753"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Reprogenix Closes RMB 500M Series A+ to Advance Diabetes Cell Therapy Pipeline","datePublished":"2025-11-21T13:39:21+00:00","dateModified":"2025-11-21T13:39:22+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48753"},"wordCount":444,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48753#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2102.webp","keywords":["Reprogenix"],"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48753#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48753","url":"https:\/\/flcube.com\/?p=48753","name":"Reprogenix Closes RMB 500M Series A+ to Advance Diabetes Cell Therapy Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48753#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48753#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2102.webp","datePublished":"2025-11-21T13:39:21+00:00","dateModified":"2025-11-21T13:39:22+00:00","description":"Reprogenix Bioscience Inc. announced the completion of an oversubscribed RMB 500\u202fmillion Series\u202fA+ financing round led by CRS Fund and joined by Yuanbio Venture Capital, ZSCO, SinoWisdom, Oriental Renaissance Capital, Lotus Lake Capital, Yuhang State\u2011owned Capital Investment, Beijing Gage, and Beicheng Fund. Proceeds will accelerate clinical advancement of its diabetes cell therapies, develop an AI\u2011driven islet differentiation platform, and expand digital manufacturing capacity.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48753#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48753"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48753#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2102.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2102.webp","width":1080,"height":608,"caption":"Reprogenix Closes RMB 500M Series A+ to Advance Diabetes Cell Therapy Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48753#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Reprogenix Closes RMB 500M Series A+ to Advance Diabetes Cell Therapy Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2102.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48753","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48753"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48753\/revisions"}],"predecessor-version":[{"id":48755,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48753\/revisions\/48755"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48754"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48753"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48753"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48753"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}